IL153078A0 - Methods for treating hepatitis delta virus infection with beta-l-2' deoxy nucleosides - Google Patents
Methods for treating hepatitis delta virus infection with beta-l-2' deoxy nucleosidesInfo
- Publication number
- IL153078A0 IL153078A0 IL15307801A IL15307801A IL153078A0 IL 153078 A0 IL153078 A0 IL 153078A0 IL 15307801 A IL15307801 A IL 15307801A IL 15307801 A IL15307801 A IL 15307801A IL 153078 A0 IL153078 A0 IL 153078A0
- Authority
- IL
- Israel
- Prior art keywords
- beta
- methods
- virus infection
- treating hepatitis
- hepatitis delta
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20753800P | 2000-05-26 | 2000-05-26 | |
PCT/US2001/017301 WO2001091737A2 (en) | 2000-05-26 | 2001-05-29 | Methods for treating hepatitis delta virus infection with beta-l-2' deoxy-nucleosides |
Publications (1)
Publication Number | Publication Date |
---|---|
IL153078A0 true IL153078A0 (en) | 2003-06-24 |
Family
ID=22771005
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15307801A IL153078A0 (en) | 2000-05-26 | 2001-05-29 | Methods for treating hepatitis delta virus infection with beta-l-2' deoxy nucleosides |
Country Status (18)
Country | Link |
---|---|
US (1) | US6596700B2 (de) |
EP (1) | EP1292313B1 (de) |
JP (1) | JP2004513070A (de) |
KR (1) | KR100854398B1 (de) |
CN (1) | CN100490818C (de) |
AT (1) | ATE275406T1 (de) |
AU (3) | AU6348401A (de) |
BR (1) | BR0111195A (de) |
CA (1) | CA2410488C (de) |
DE (1) | DE60105424T2 (de) |
EA (1) | EA005890B1 (de) |
ES (1) | ES2227203T3 (de) |
HK (1) | HK1050999A1 (de) |
IL (1) | IL153078A0 (de) |
MX (1) | MXPA02011641A (de) |
TR (1) | TR200402565T4 (de) |
WO (1) | WO2001091737A2 (de) |
ZA (2) | ZA200210100B (de) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA986614B (en) * | 1997-07-25 | 1999-01-27 | Gilead Sciences | Nucleotide analog composition |
DK2415776T3 (en) * | 1998-08-10 | 2016-07-04 | Novartis Ag | Beta-L-2'-deoxy nucleosides for the treatment of Hepatitis B |
US6444652B1 (en) | 1998-08-10 | 2002-09-03 | Novirio Pharmaceuticals Limited | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
US20020056123A1 (en) * | 2000-03-09 | 2002-05-09 | Gad Liwerant | Sharing a streaming video |
JP2003532643A (ja) | 2000-04-13 | 2003-11-05 | フアーマセツト・リミテツド | 肝炎ウイルス感染症を治療するための3’−または2’−ヒドロキシメチル置換ヌクレオシド誘導体 |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
KR20030036189A (ko) | 2000-05-26 | 2003-05-09 | 이데닉스(케이만)리미티드 | 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물 |
US6787526B1 (en) * | 2000-05-26 | 2004-09-07 | Idenix Pharmaceuticals, Inc. | Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides |
PT1411954E (pt) * | 2000-10-18 | 2011-03-16 | Pharmasset Inc | Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal |
DE14169110T1 (de) * | 2002-06-28 | 2022-05-12 | Centre National De La Recherche Scientifique -Cnrs- | Modifizierte 2'- und 3'-Nukleosid-Prodrugs zur Behandlung von Flaviridae-Infektionen |
US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
RS114104A (en) * | 2002-06-28 | 2007-02-05 | Idenix (Cayman) Limited, | 2' and 3'-nucleoside prodrugs for treating flaviviridae infections |
AU2003248748A1 (en) * | 2002-06-28 | 2004-01-19 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
CN101172993A (zh) * | 2002-06-28 | 2008-05-07 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒感染的2′-c-甲基-3′-o-l-缬氨酸酯核糖呋喃基胞苷 |
BR0314259A (pt) * | 2002-09-13 | 2005-07-26 | Idenix Cayman Ltd | ß-l-2'-desoxinucleosìdeos para o tratamento de cepas de hbv resistentes e terapias combinadas |
US7148349B2 (en) * | 2002-10-31 | 2006-12-12 | Metabasis Therapeutics, Inc. | Cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs |
KR20050088079A (ko) | 2002-11-15 | 2005-09-01 | 이데닉스 (케이만) 리미티드 | 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이 |
CN1303089C (zh) * | 2002-11-19 | 2007-03-07 | 天津药物研究院 | 阿德福韦酯结晶形态及其制备方法 |
CN1330373C (zh) * | 2002-12-02 | 2007-08-08 | 美德(江西)生物科技有限公司 | 含alfa-干扰素,阿地福韦和二脱氧氟硫代胞嘧啶的药物组合物 |
EP2319853B1 (de) * | 2002-12-12 | 2014-03-12 | IDENIX Pharmaceuticals, Inc. | Verfahren zur Herstellung von 2 -verzweigten Nucleosiden |
US7429572B2 (en) | 2003-05-30 | 2008-09-30 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
WO2006031725A2 (en) | 2004-09-14 | 2006-03-23 | Pharmasset, Inc. | Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
CN101242842A (zh) | 2005-06-17 | 2008-08-13 | 诺瓦提斯公司 | Sanglifehrin在hcv中的用途 |
US7781576B2 (en) * | 2005-12-23 | 2010-08-24 | Idenix Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
GB0623493D0 (en) | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
EP2376088B1 (de) | 2008-12-23 | 2017-02-22 | Gilead Pharmasset LLC | 6-O-Substituierte-2-Amino-Purin-Nukleosid-Phosphoramidate |
EA019295B1 (ru) | 2008-12-23 | 2014-02-28 | Джилид Фармассет, Ллс. | Соединения пуриновых нуклеозидов и способ их получения |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
JP2013527145A (ja) | 2010-03-31 | 2013-06-27 | ギリード・ファーマセット・エルエルシー | リン含有活性化剤の立体選択的合成 |
BR112013005872A2 (pt) | 2010-09-22 | 2019-09-24 | Alios Biopharma Inc | compostos, composição farmacêutica e respectivos usos |
AR084044A1 (es) | 2010-11-30 | 2013-04-17 | Pharmasset Inc | Compuestos 2’-espiro-nucleosidos |
US9622967B2 (en) * | 2010-12-10 | 2017-04-18 | Sigmapharm Laboratories, Llc | Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs |
JP6073897B2 (ja) | 2011-09-16 | 2017-02-01 | ギリアド ファーマセット エルエルシー | Hcvを処置するための方法 |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
AU2012358804B2 (en) | 2011-12-22 | 2018-04-19 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
US8916538B2 (en) | 2012-03-21 | 2014-12-23 | Vertex Pharmaceuticals Incorporated | Solid forms of a thiophosphoramidate nucleotide prodrug |
EP2827876A4 (de) | 2012-03-22 | 2015-10-28 | Alios Biopharma Inc | Pharmazeutische kombinationen mit einem thionucleotidanalog |
ES2771458T3 (es) | 2013-01-31 | 2020-07-06 | Gilead Pharmasset Llc | Formulación de combinación de dos compuestos antivirales |
WO2015014442A1 (en) * | 2013-07-31 | 2015-02-05 | Merck Patent Gmbh | Oxoquinazolinyl-butanamide derivatives |
PL3650014T3 (pl) | 2013-08-27 | 2022-01-31 | Gilead Pharmasset Llc | Preparat złożony dwóch związków przeciwwirusowych |
EP3105238A4 (de) | 2014-02-13 | 2017-11-08 | Ligand Pharmaceuticals, Inc. | Organische verbindungen und deren verwendungen |
EP3164136A4 (de) | 2014-07-02 | 2018-04-04 | Ligand Pharmaceuticals, Inc. | Prodrug-verbindungen und verwendungen davon |
ES2808148T3 (es) | 2015-06-17 | 2021-02-25 | Univ Columbia | Terapia de desoxinucleósidos para enfermedades causadas por grupos de nucleótidos desequilibrados incluyendo síndromes de agotamiento de ADN mitocondrial |
WO2017040766A1 (en) | 2015-09-02 | 2017-03-09 | Abbvie Inc. | Anti-viral tetrahydrofurane derivatives |
CN108264524A (zh) * | 2016-12-31 | 2018-07-10 | 正大天晴药业集团股份有限公司 | 恩曲他滨膦酸酯化合物 |
RU2644156C1 (ru) | 2017-02-28 | 2018-02-08 | Александр Васильевич Иващенко | Пролекарство ингибитора NS5B HCV полимеразы, способ его получения и применения |
RU2662160C9 (ru) * | 2017-07-03 | 2018-10-22 | Александрович Иващенко Андрей | Комбинированный лекарственный препарат для терапии вирусных инфекций |
EP3651734A1 (de) | 2017-07-11 | 2020-05-20 | Gilead Sciences, Inc. | Zusammensetzungen mit einem rna-polymerasehemmer und cyclodextrin zur behandlung von virusinfektionen |
RU2662161C1 (ru) * | 2017-08-11 | 2018-07-24 | Васильевич Иващенко Александр | Ингибитор входа вируса гепатита и фармацевтическая композиция для лечения гепатита |
CN111788196A (zh) | 2018-01-09 | 2020-10-16 | 配体药物公司 | 缩醛化合物及其治疗用途 |
JP2023512656A (ja) | 2020-01-27 | 2023-03-28 | ギリアード サイエンシーズ, インコーポレイテッド | SARS CoV-2感染を治療するための方法 |
TWI785528B (zh) | 2020-03-12 | 2022-12-01 | 美商基利科學股份有限公司 | 1’-氰基核苷之製備方法 |
KR20220164784A (ko) | 2020-04-06 | 2022-12-13 | 길리애드 사이언시즈, 인코포레이티드 | 1'-시아노 치환된 카르바뉴클레오시드 유사체의 흡입 제형 |
EP4157272A1 (de) | 2020-05-29 | 2023-04-05 | Gilead Sciences, Inc. | Verfahren zur behandlung von remdesivir |
TWI819321B (zh) | 2020-06-24 | 2023-10-21 | 美商基利科學股份有限公司 | 1'-氰基核苷類似物及其用途 |
IL300412A (en) | 2020-08-24 | 2023-04-01 | Gilead Sciences Inc | Phospholipid compounds and their uses |
TW202228722A (zh) | 2020-08-27 | 2022-08-01 | 美商基利科學股份有限公司 | 用於治療病毒感染之化合物及方法 |
TWI811812B (zh) | 2020-10-16 | 2023-08-11 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
EP4320128A1 (de) | 2022-03-02 | 2024-02-14 | Gilead Sciences, Inc. | Verbindungen und verfahren zur behandlung von virusinfektionen |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8802687D0 (sv) | 1988-07-20 | 1988-07-20 | Astra Ab | Nucleoside derivatives |
JP3693357B2 (ja) * | 1993-04-09 | 2005-09-07 | 峯郎 実吉 | 逆転写酵素阻害剤 |
WO1996011204A1 (de) | 1994-10-07 | 1996-04-18 | Max-Delbrück-Centrum für Molekulare Medizin | NEUE β-L-NUCLEOSIDE UND IHRE VERWENDUNG |
DK2415776T3 (en) | 1998-08-10 | 2016-07-04 | Novartis Ag | Beta-L-2'-deoxy nucleosides for the treatment of Hepatitis B |
-
2001
- 2001-05-29 KR KR1020027015985A patent/KR100854398B1/ko not_active IP Right Cessation
- 2001-05-29 CN CNB018134297A patent/CN100490818C/zh not_active Expired - Fee Related
- 2001-05-29 US US09/867,110 patent/US6596700B2/en not_active Expired - Fee Related
- 2001-05-29 DE DE60105424T patent/DE60105424T2/de not_active Expired - Fee Related
- 2001-05-29 BR BR0111195-7A patent/BR0111195A/pt not_active Application Discontinuation
- 2001-05-29 ES ES01937785T patent/ES2227203T3/es not_active Expired - Lifetime
- 2001-05-29 AU AU6348401A patent/AU6348401A/xx active Pending
- 2001-05-29 EA EA200201263A patent/EA005890B1/ru not_active IP Right Cessation
- 2001-05-29 CA CA002410488A patent/CA2410488C/en not_active Expired - Fee Related
- 2001-05-29 EP EP01937785A patent/EP1292313B1/de not_active Expired - Lifetime
- 2001-05-29 TR TR2004/02565T patent/TR200402565T4/xx unknown
- 2001-05-29 IL IL15307801A patent/IL153078A0/xx not_active IP Right Cessation
- 2001-05-29 MX MXPA02011641A patent/MXPA02011641A/es active IP Right Grant
- 2001-05-29 WO PCT/US2001/017301 patent/WO2001091737A2/en active IP Right Grant
- 2001-05-29 AU AU2001263484A patent/AU2001263484B2/en not_active Ceased
- 2001-05-29 JP JP2001587753A patent/JP2004513070A/ja active Pending
- 2001-05-29 AT AT01937785T patent/ATE275406T1/de not_active IP Right Cessation
-
2002
- 2002-12-12 ZA ZA200210100A patent/ZA200210100B/en unknown
-
2003
- 2003-04-22 HK HK03102836A patent/HK1050999A1/xx not_active IP Right Cessation
-
2004
- 2004-06-01 ZA ZA200404304A patent/ZA200404304B/xx unknown
-
2006
- 2006-12-21 AU AU2006252214A patent/AU2006252214A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2001263484B2 (en) | 2006-12-14 |
EP1292313B1 (de) | 2004-09-08 |
ZA200404304B (en) | 2005-03-30 |
HK1050999A1 (en) | 2003-07-18 |
MXPA02011641A (es) | 2004-07-30 |
ZA200210100B (en) | 2004-06-22 |
WO2001091737A3 (en) | 2002-05-30 |
EA200201263A1 (ru) | 2003-06-26 |
EP1292313A2 (de) | 2003-03-19 |
KR100854398B1 (ko) | 2008-08-26 |
BR0111195A (pt) | 2004-07-20 |
ES2227203T3 (es) | 2005-04-01 |
JP2004513070A (ja) | 2004-04-30 |
EA005890B1 (ru) | 2005-06-30 |
KR20030031487A (ko) | 2003-04-21 |
ATE275406T1 (de) | 2004-09-15 |
US6596700B2 (en) | 2003-07-22 |
WO2001091737A2 (en) | 2001-12-06 |
DE60105424D1 (de) | 2004-10-14 |
TR200402565T4 (tr) | 2004-12-21 |
CN1444483A (zh) | 2003-09-24 |
AU6348401A (en) | 2001-12-11 |
CN100490818C (zh) | 2009-05-27 |
CA2410488A1 (en) | 2001-12-06 |
DE60105424T2 (de) | 2005-09-22 |
CA2410488C (en) | 2009-10-27 |
AU2006252214A1 (en) | 2007-01-18 |
US20020035085A1 (en) | 2002-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL153078A0 (en) | Methods for treating hepatitis delta virus infection with beta-l-2' deoxy nucleosides | |
SG156517A1 (en) | Methods and compositions for treating hepatitis c virus | |
WO2003026589A3 (en) | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides | |
WO2003063771A3 (en) | N4-acylcytosine nucleosides for treatment of viral iinfections | |
AP1727A (en) | Methods and compositions for treating flaviviruses and pestiviruses. | |
WO2001032153A3 (en) | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues | |
AU3216695A (en) | Lipid analogs for treating viral infections | |
AU2001249564A1 (en) | Method of treating hepatitis delta viral infection | |
ZA991029B (en) | Composition and methods for treatment of hiv infections. | |
HK1041215A1 (en) | Use of thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir in manufacturing pharmaceutical combination preparations for treating hepatitis b infection. | |
WO2004013298A3 (en) | 2',3'-dideoxynucleoside analogues for the treatment or prevention of flavivitridae infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
MM9K | Patent not in force due to non-payment of renewal fees |